Menu

Recent Interviews

Ryan Jackson, CEO, Newlox Gold Ventures Corp.

Ryan Jackson
CEO | Newlox Gold Ventures Corp.
60 Laurie Crescent, V7S 1B7 West Vancouver (CAN)

info@newloxgold.com

+1 778 738 0546

Newlox CEO Ryan Jackson on building a green gold producer with a rapid growth trajectory


Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


18. September 2020 | 06:00 CET

BioNTech, CureVac, EXMceuticals - reaching their goal with government support

  • Covid-19

In the fight against the spread of the Corona Pandemic, a great deal of commitment is required from companies. This situation also offers the opportunity to rethink and change existing work processes and procedures. Product ranges are being expanded and new possibilities and active ingredients are being sought to combat Covid-19. Above all, the common good of all is the primary focus of political institutions and for this reason they are not letting research-based companies down and are attracting them with special permits and subsidies. Ultimately, everyone around the world will likely benefit from this.

time to read: 2 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Natural remedies against corona viruses

In the fight against the spread of the corona virus, the Canadian bioscience company EXMceuticals is looking for ways in which naturally occurring bioactive substances can be used to combat the virus on a scalable basis. In this context, the company and two other partners in Portugal have set up the consortium called "BioBlockCOVID" in order to jointly develop functional, natural and innovative biocide formulations. The European Union and Portugal are supporting the consortium by providing the project with grants of ~EUR 0.3 million.

The project leader, Susana Santos, Chief Innovation Officer of EXMceuticals Portugal, commented: "We are very confident that the concepts outlined in BioBlockCovid will result in new practical and state of the art solutions to help control the pandemic. Alongside our partners working in therapies and vaccines, we intend to contribute with practical solutions to this very serious global problem. EXM's overall mission is to combine safe, natural and bioactive materials with advanced and sustainable technologies to create products with significant health and wellness benefits."

Production capacity to be increased

BioNTech SE of Mainz announced yesterday that the company is acquiring a production facility in Marburg from Novartis AG. The plant is expected to produce up to 750 million doses of Covid-19 vaccine next year, making it the largest production facility in Europe. This plant is one of three production facilities of BioNTech. With the purchase, the company is not only acquiring the necessary equipment, but is also taking on around 300 experienced employees who are currently working at the site.

"This acquisition reflects BioNTech's commitment to significantly expanding its manufacturing capacity in order to supply a potential vaccine worldwide upon authorization or approval. We are working closely with Novartis to prepare for a smooth transition, and we look forward to welcoming the new members of our team and tapping into their impressive skills and expertise. From a strategic standpoint, the new site will bolster our vertically integrated business model with in-house manufacturing capabilities for mRNA manufacturing as well as vaccine formulation," said Sierk Poetting, M.D., Chief Financial Officer and Chief Operating Officer of BioNTech.

Reaching its goal with government support

Newcomer, CureVac, recently announced that the German Federal Ministry of Education and Research is expected to receive up to EUR 252 million for the development of a Covid-19 vaccine. In July 2020, Federal Minister Anja Karliczek had announced the recognition of CureVac's eligibility for funding. According to a milestone agreement, the company expects to receive EUR 103 million in 2020 and EUR 149 million in 2021. The government support is a special program to accelerate research and development of urgently needed vaccines against SARS-CoV-2.

Dr. Franz-Werner Haas, Chief Executive Officer of CureVac, commented: "CureVac highly appreciates this significant and important financial support, which is expected to enable us to accelerate the development of our CVnCoV vaccine candidate as well as to increase our manufacturing capacity and, hence, to fight the COVID-19 pandemic. Given the significant costs related to the development of a safe and effective vaccine as well as to the extension of the manufacturing capacity, we believe that this grant can substantially support our efforts to produce and develop a safe and effective vaccine in high volume as quickly as possible."


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

21. October 2020 | 12:42 CET | by Stefan Feulner

BioNTech, Valeo Pharma, Pfizer - Starting signal!

  • Covid-19

Who will make the race for the first approved Corona vaccine? Russia, China, and several North American suppliers are fighting for a place in the sun. The second and third parties should also benefit from the approval, as the demand is enormous among the nearly 8 billion inhabitants of the earth. One thing is clear; the winners of this almost macabre-sounding "Corona contest" will go through the roof. Those who receive late approval or no approval at all risk extinction. Admittedly, the world is looking at the long-awaited miracle cure. But there are easier ways for every individual to protect themselves against viruses.

Read

23. September 2020 | 09:05 CET | by Mario Hose

BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?

  • Covid-19

When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.

Read

11. September 2020 | 09:59 CET | by Mario Hose

BioNTech, CureVac, Valeo Pharma - Growth after capital injection

  • Covid-19

Anyone working in the medical sector knows that the development of therapies and products usually costs a lot of time and especially a lot of money. In the race against the spread of the current Corona pandemic, there are major changes in the industry, because whoever comes to the market with a product first is de facto guaranteed high sales and profits. However, there is not much time left for the development of a vaccine against Covid-19 and to reduce the economic damage, researching companies have virtually unlimited amounts of money available. Whoever finds a solution against Covid-19 will certainly have the right team in the starting blocks in the fight against the subsequent Corona viruses.

Read